The Pharmaceutical Industry in the UK has been hit by the massive increase in the cost of Regulatory Changes. The pharmacy companies in the UK may suffer with the loss of EU collaborative research. There is uncertainty what the effect on no MRA and no FMD will be in the UK next year with the Brexit cut off date quickly approching.
Jan 1st is looming, with all sorts of requirements for MA holders. Labelling will need to be considered, Importers will require a RPi, and existing wholesalers will have to alter the scope of their authorisation to continue importing medicines from the EU.
It is inevitable prices will have to be increased and the big question is will UK medicines remain competitive?
